QC
ACET icon

Quadrature Capital’s Adicet Bio ACET Stock Holding History

Quadrature Capital’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$313K Buy
+36,193
New +$285K ﹤0.01% 1187

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Quadrature Capital's ACET Position: Q2 2026 in Review

Quadrature Capital opened a new position in Adicet Bio (ACET) in Q2 2026: 36,193 shares worth $313K. The stake represents ﹤0.01% of the portfolio and ranks #1187 among its holdings.

56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • Quadrature Capital held 36,193 shares of Adicet Bio worth $313K as of Q2 2026.
  • Adicet Bio was a new Quadrature Capital position in Q2 2026.
  • Adicet Bio made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1187 holding.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.